Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Autor: Diego Pérez Parente, L. Crama, Begoña Campos-Balea, David Vicente-Baz, Pedro Ruiz-Gracia, Manuel Cobo Dols, Javier de Castro Carpeño, Bartomeu Massuti
Přispěvatelé: [Campos-Balea,B] Oncology, Hospital Universitario Lucus Augusti (HULA), Lugo, Spain. [de Castro Carpeño,J] Oncology, Hospital Universitario La Paz, Madrid, Spain. [Massutí,B] Oncology, Hospital Universitario Alicante (ISABIAL), Alicante, Spain. [Vicente-Baz,D] Oncology, Hospital Universitario Virgen Macarena, Seville, Spain. [Pérez Parente, Ruiz-Gracia,P, Crama,L] Lung Cancer. Medical Affairs Department, Roche Farma S.A, Madrid, Spain. [Cobo Dols,M] Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA, Málaga, Spain.
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Lung adenocarcinoma
Male
Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Registries::SEER Program [Medical Subject Headings]
Metastasis
Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]
0302 clinical medicine
Surveillance
Epidemiology
and End Results

Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms
Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings]

Neoplasm Metastasis
prognostic factor
Metástasis neoplásica
Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]
Cause of death
Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings]
Hazard ratio
Pronóstico
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
030220 oncology & carcinogenesis
Adenocarcinoma
Original Article
Female
non‐small cell lung cancer
Pulmonary and Respiratory Medicine
medicine.medical_specialty
overall survival
Check Tags::Male [Medical Subject Headings]
Adenocarcinoma of Lung
Carcinoma de pulmón de células no pequeñas
Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings]
lcsh:RC254-282
03 medical and health sciences
Internal medicine
Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings]
Adenocarcinoma del pulmón
medicine
metastasis
Humans
Lung cancer
non-small cell lung cancer
Aged
Proportional hazards model
business.industry
Cancer
Original Articles
Anatomy::Respiratory System::Lung [Medical Subject Headings]
medicine.disease
030104 developmental biology
Check Tags::Female [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]

business
SEER Program
Zdroj: Thoracic Cancer, Vol 11, Iss 11, Pp 3357-3364 (2020)
Thoracic Cancer
Popis: Background Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real‐world clinical practice. Methods Patients were selected from the Surveillance Epidemiology and End Results (SEER) database. Chi‐square bivariate analysis was used for the association of binary qualitative variables. A multivariate Cox regression analysis was performed to determine the impact of these prognostic factors on OS. Results A total of 46 030 patients were included (51.3% men, mean age 67.03 ± 11.6), of whom 41.3% presented with metastases in bone, 28.9% in brain, 17.1% in liver and 31.8% in lung. Patients with liver metastases presented with two or more metastatic sites more frequently than patients without liver metastases (P
In this study we identified male sex, age = 65 years, lack of family support and liver and brain metastases as poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC. The presence of liver metastases emerged as the worst prognostic factor. Consequently, it should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy.
Databáze: OpenAIRE